
Contigency plans in place while Smith & Nephew boss has cancer treatment
pharmafile | February 1, 2016 | Appointment | Manufacturing and Production | Olivier Bohuon, Smith & Nephew, medical devices
Medical technology firm Smith & Nephew has announced that chief executive Olivier Bohuon has been diagnosed with a ‘highly treatable form’ of cancer.
Bohuon will remain chief executive and be actively involved in running the company through much of his treatment period, which will begin later this month. The treatment will include chemotherapy, and is expected to be completed by late autumn.
The Board has approved provisional governance procedures to ensure the effective operation of Smith & Nephew during the treatment period, including Chairman Roberto Quarta providing executive oversight if required.
Roberto Quarta, chairman of Smith & Nephew, says: “Olivier has set a clear strategy that is invigorating Smith & Nephew’s growth profile. I am confident that Olivier and his team will continue to execute the plan successfully. Our thoughts are with him as he undergoes treatment.”
Olivier will present Smith & Nephew’s full year and Q4 results on Thursday 4 February 2016 as normal.
Related Content

FDA approves Abbott’s Assert-IQ insertable cardiac monitor
Abbott has announced that the US Food and Drug Administration (FDA) has granted its clearance …

FDA to end controversial “alternative summary reporting” of medical devices in bid to boost transparency
The FDA has revealed that it plans to terminate its “alternative summary reporting” programme which …

Could the new EU Medical Devices Regulation put the UK MedTech industry in peril?
Gill Jennings and Every’s Fiona Stevens discusses recent developments in medical devices regulation and the …






